scispace - formally typeset
Open AccessJournal ArticleDOI

Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010

Reads0
Chats0
TLDR
Examination of the association between medical cannabis laws and opioid analgesic overdose mortality in each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time.
Abstract
Importance Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mortality related to opioid analgesics in states that have enacted them. Objective To determine the association between the presence of state medical cannabis laws and opioid analgesic overdose mortality. Design, Setting, and Participants A time-series analysis was conducted of medical cannabis laws and state-level death certificate data in the United States from 1999 to 2010; all 50 states were included. Exposures Presence of a law establishing a medical cannabis program in the state. Main Outcomes and Measures Age-adjusted opioid analgesic overdose death rate per 100 000 population in each state. Regression models were developed including state and year fixed effects, the presence of 3 different policies regarding opioid analgesics, and the state-specific unemployment rate. Results Three states (California, Oregon, and Washington) had medical cannabis laws effective prior to 1999. Ten states (Alaska, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Mexico, Rhode Island, and Vermont) enacted medical cannabis laws between 1999 and 2010. States with medical cannabis laws had a 24.8% lower mean annual opioid overdose mortality rate (95% CI, −37.5% to −9.5%; P  = .003) compared with states without medical cannabis laws. Examination of the association between medical cannabis laws and opioid analgesic overdose mortality in each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time: year 1 (−19.9%; 95% CI, −30.6% to −7.7%; P  = .002), year 2 (−25.2%; 95% CI, −40.6% to −5.9%; P  = .01), year 3 (−23.6%; 95% CI, −41.1% to −1.0%; P  = .04), year 4 (−20.2%; 95% CI, −33.6% to −4.0%; P  = .02), year 5 (−33.7%; 95% CI, −50.9% to −10.4%; P  = .008), and year 6 (−33.3%; 95% CI, −44.7% to −19.6%; P Conclusions and Relevance Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates. Further investigation is required to determine how medical cannabis laws may interact with policies aimed at preventing opioid analgesic overdose.

read more

Citations
More filters
Posted ContentDOI

Prescription Opioid Distribution After The Legalization Of Recreational Marijuana In Colorado, 2007-2017

TL;DR: In this paper, the authors examined the association between the legalization of Colorados recreational marijuana and prescription opioid distribution trends and two states that have not legalized recreational marijuana were selected for comparison.

Essays on Medical Marijuana Laws, Health Insurance and Health Care Utilization

Pelin Ozluk
TL;DR: This dissertation examines how different policy interventions contributed to the rise in health care utilization and prescribed opioids in U.S. society and estimates the effects of MMLs on prescription drug utilization, with a focus on opioids.
Journal ArticleDOI

Assessment of Medical Cannabis and Health-Related Quality of Life

TL;DR: In a case series of 3148 patients, significant improvements were reported on all 8 domains of the 36-Item Short Form Health Survey health-related quality of life assessment after commencing treatment with medical cannabis as discussed by the authors .
Book ChapterDOI

The Health Shadow Price and Economically Meaningful Threshold Values

TL;DR: The health shadow price of Pekarsky (2012, 2015) is shown to provide a pathway to allocative efficiency by establishing an economically meaningful value for the threshold value for effects in net benefit assessment, central to all decision making across joint research, reimbursement and regulatory decisions in practice.
Journal ArticleDOI

United States marijuana legalization and opioid mortality epidemic during 2010-2020 and pandemic implications.

TL;DR: The United States opioid mortality rate was compared in states and District of Columbia that had implemented marijuana legalization with states that had not, by applying joinpoint methodology to Centers for Disease Control and Prevention data as mentioned in this paper .
References
More filters
Posted Content

Mostly Harmless Econometrics: An Empiricist's Companion

TL;DR: The core methods in today's econometric toolkit are linear regression for statistical control, instrumental variables methods for the analysis of natural experiments, and differences-in-differences methods that exploit policy changes.
Journal ArticleDOI

Adverse Health Effects of Marijuana Use

TL;DR: As marijuana use becomes legal in some states, the dominant public opinion is that marijuana is a harmless source of mood alteration, but enough information is available to cause concern.
Journal ArticleDOI

The economic costs of pain in the United States.

TL;DR: The national cost of pain ranges from $560 to $635 billion, larger than the cost of the nation's priority health conditions and the annual cost of heart disease, cancer, and diabetes.

Vital Signs: Overdoses of Prescription Opioid Pain Relievers - United States, 1999-2008

TL;DR: Wide variation among states in the nonmedical use of OPR and overdose rates cannot be explained by underlying demographic differences in state populations but is related to wide variations in OPR prescribing.
Journal ArticleDOI

Association between opioid prescribing patterns and opioid overdose-related deaths.

TL;DR: Among patients receiving opioid prescriptions for pain, higher opioid doses were associated with increased risk of opioid overdose death, and receiving both as-needed and regularly scheduled doses was not associated with overdose risk after adjustment.
Related Papers (5)